IntrinsicIntrinsic
← All summaries

Aspire Biopharma Holdings, Inc.

ASBPW
Financials & Chart →

Business Summary

Aspire Biopharma Holdings, Inc. is an early-stage biopharmaceutical company focused on developing and marketing novel sublingual delivery mechanisms for known drugs and nutraceuticals . The company's core business model involves generating revenue through the development and marketing of these products, with potential future revenue streams from licensing or collaboration agreements that could include development funding, upfront and milestone payments, and royalties . Aspire does not currently have any licensing or collaboration agreements . The company primarily targets the heart attack and stroke prevention market for its aspirin products and also develops nutraceuticals like melatonin and caffeine supplements .

Aspire's product pipeline is centered around its patent-pending sublingual delivery technologies, designed to address emergencies, drug efficacy, dosage management, and response time by allowing rapid sublingual absorption, bypassing the gastrointestinal tract . This technology facilitates the development of products in a soluble, pH-neutral, fast-acting powder or granule form . The company has two primary patent properties covering its aspirin formulation technology: application number PCT/US2024/022318, with a nominal expiration of March 29, 2044 , and application number 63/702,381, filed in October 2024, with a nominal expiration of October 1, 2045 . These patent applications cover composition of matter (formulations), including product-by-process coverage, as well as uses of the formulations .

The company's lead product candidate is a high-dose sublingual aspirin, informally referred to as "Instaprin" , which has completed a successful clinical trial in July 2025 . This trial demonstrated faster aspirin bioavailability and quicker anti-coagulant properties compared to standard oral aspirin, without the associated gastrointestinal toxicity . Aspire plans to submit a 505(b)(2) New Drug Application (NDA) to the FDA for this prescription-strength high-dose aspirin product in late 2026 . Other products in development include a sublingually administered melatonin sleep-aid in 3mg, 5mg, and 10mg doses , sublingually administered vitamins D, E, and K , a sublingual ED (erectile dysfunction) product , and caffeine products marketed under the "Buzz Bomb" trademark . Additionally, formulations for anti-nausea products (meclizine and ondansetron), alprazolam, clopidogrel, microdose nicotine, and semaglutide are being developed .

For the fiscal year ended December 31, 2025, Aspire reported net revenue of $6,202 and a cost of revenue of $6,318 , resulting in a gross margin of $(116) . Operating expenses totaled $19,351,175 , leading to a loss from operations of $(19,351,291) . The net loss for the year was $(24,480,848) , with basic and diluted net loss per share of $(16.38) . As of December 31, 2025, the company had cash of $1,003,904 , an accumulated deficit of $27,258,081 , and a working capital deficit of $6,280,667 .

Comparing 2025 to 2024, net revenue increased from $0 in 2024 to $6,202 in 2025 , as the company commenced product sales in the third quarter of 2025 . General and administrative expenses significantly increased by $16,697,011, from $940,421 in 2024 to $17,637,432 in 2025 , primarily due to professional services, including legal, consulting, stock-based compensation, and accounting . Research and development expenses rose by $779,558, from $144,356 in 2024 to $923,914 in 2025 , reflecting increased personnel and supplies costs for product development . Sales and marketing expenses increased by $663,735, from $126,094 in 2024 to $789,829 in 2025 , driven by investor awareness and product sampling . Interest expense increased from $(97,988) in 2024 to $(8,531,275) in 2025 , mainly due to accrued interest on convertible notes, subscription agreements, and amortization of debt discount . The company also recognized a change in fair value of liabilities of $3,860,889 in 2025 , an initial recognition of forward purchase liability of $(95,062) , and a loss on extinguishment of debt of $(364,109) in 2025, none of which were present in 2024.

Significant operational developments during the period include the consummation of a reverse recapitalization on February 17, 2025, where PowerUp Acquisition Corp. changed its name to Aspire Biopharma Holdings, Inc. and Aspire Biopharma, Inc. became a wholly-owned subsidiary . The company entered into a Securities Purchase Agreement on February 17, 2025, issuing two 20% original issue discount senior secured convertible debentures in an aggregate principal amount of $3,750,000 , which were subsequently paid in full by February 6, 2026 . An August 2025 Securities Purchase Agreement resulted in the sale of convertible notes with an aggregate principal amount of $9,687,500 for a subscription price of $7,750,000 , which were fully converted into 2,219,932 shares of common stock in October and November 2025 . A Second ELOC Agreement was entered into on November 11, 2025, allowing the company to direct Arena Business Solutions Global SPC II, Ltd. to purchase up to $100,000,000 in common stock over 24 months . The company also regained compliance with Nasdaq's Bid Price Rule on February 3, 2026, and the MVLS Rule on February 18, 2026 . In January 2026, the company entered into Exchange Agreements to convert approximately $1.75 million in debt into common stock , and all of this debt was subsequently converted . A 1-for-40 reverse stock split was effected on January 16, 2026 .

Business Outlook

Aspire expects to generate revenue through the development and marketing of drugs and nutraceuticals utilizing its novel sublingual delivery technology . The company may also pursue license or collaboration agreements with other companies, which could provide development funding, upfront and milestone payments, and royalties, becoming a significant source of revenue .

A major growth area for Aspire is its high-dose sublingual aspirin product, for which a 505(b)(2) submission to the FDA is planned for late 2026 . This product is expected to target the heart attack and stroke prevention market, with the company considering both a targeted hospital and/or specialty care sales force and licensing opportunities . The company's clinical trials for this product demonstrated faster aspirin bioavailability and quicker anti-coagulant properties compared to standard oral aspirin, without gastrointestinal toxicity . Aspire intends to conduct an additional clinical trial starting in approximately June 2026, involving approximately 32 healthy human volunteers, to evaluate the pharmacodynamic effect of a single dose of its high-dose aspirin on platelet inhibition compared to standard oral aspirin . The proposed primary endpoint for this trial is time to TXB2 inhibition .

Another growth area is the development and commercialization of various nutraceutical and drug products using its sublingual delivery technology. This includes a melatonin sleep-aid product in 3mg, 5mg, and 10mg doses, for which limited testing has been completed and licensing possibilities are being explored . Sublingually administered vitamins D, E, and K are also in formulation . The company is developing a sublingual ED (erectile dysfunction) product, with FDA approval likely taking at least 2-3 years . Caffeine products, marketed under the "Buzz Bomb" trademark, began initial sales in the third quarter of 2025 , and a manufacturing contract for 2,000,000 units commenced marketing on January 15, 2026 . Formulations for anti-nausea products (meclizine and ondansetron), alprazolam, clopidogrel, microdose nicotine, and semaglutide are also in development, with plans to take several of these to market as research and development, market conditions, and company funding dictate .

Operationally, Aspire expects its general and administrative expenses to increase in future periods commensurate with the expected growth of its business and increased expenditures associated with its status as an exchange-listed public company . Similarly, research and development expenses are expected to increase in future periods due to continued product development , and sales and marketing expenses are also projected to rise with business growth . The company currently contracts with third parties for manufacturing its product candidates for preclinical studies, clinical trials, and sale, and plans to continue this approach . To meet projected commercial manufacturing needs, current third-party manufacturers will need to increase their scale of production, or the company will need to secure alternate suppliers . Aspire has entered into a manufacturing agreement with Microsize in January 2026 to manufacture aspirin products for the next round of clinical trials .

Aspire's future capital requirements are substantial and depend on factors such as the scope, progress, results, and costs of research and development, preclinical studies, and clinical trials; the timing and costs of obtaining regulatory approvals; commercialization activities, including marketing, sales, and distribution; manufacturing costs; and the ability to establish and maintain strategic licensing or other arrangements . The company intends to raise additional capital through issuances of additional equity under new and existing agreements . The company also entered into a Second ELOC Agreement in November 2025, which grants it the right, but not the obligation, to direct Arena Business Solutions Global SPC II, Ltd. to purchase up to $100,000,000 in common stock over 24 months .

Risk Factors

Aspire faces several material risks, including a limited operating history and a history of net losses, with expectations of continued substantial and increasing net losses in the foreseeable future, particularly if difficulties in obtaining capital persist . The company will require substantial additional financing to achieve its goals, and a failure to obtain this necessary capital could force delays, limitations, reductions, or termination of product development or commercialization efforts . The biopharmaceutical industry is characterized by rapidly advancing technologies and intense competition from major pharmaceutical, specialty pharmaceutical, and biotechnology companies, many of which have substantially greater financial, technical, and human resources . Aspire's technology platforms and product candidates are based on novel technologies, and the regulatory approval pathway for sublingual aspirin is unproven, as all previously approved aspirin products were administered orally . Clinical development is a lengthy, expensive process with uncertain outcomes, and earlier study results may not predict future clinical trial success, potentially leading to delays or failure to demonstrate adequate safety and efficacy . Undesirable side effects from product candidates could halt clinical development, prevent regulatory approval, or limit commercial potential . The company relies on third parties to conduct clinical trials and for manufacturing, which exposes it to risks if these third parties fail to perform their contractual duties, meet deadlines, or comply with regulatory standards like cGMP . International trade disputes, including U.S. trade tariffs and retaliatory tariffs, could adversely impact the business by increasing costs for tenants who sell imported goods or by causing inflationary pressures on materials for redevelopment projects . The continuing military action in Ukraine and the war between Israel and Hamas could materially and adversely affect the company's financial position and operations, particularly its ability to raise debt and equity finance due to increased market volatility and decreased availability of third-party financing . The company's reputation could be negatively impacted by negative publicity, including the past conviction of Instaprin Pharmaceuticals' former CEO for securities fraud, especially if Aspire chooses to use the "Instaprin" trademark . Cybersecurity threats, attacks, and other disruptions, including sophisticated malware and phishing, could lead to breaches of data security, loss of critical data, and performance delays .

Management Priorities

Management's message to shareholders emphasizes Aspire's position as an early-stage biopharmaceutical and supplements company focused on developing and marketing disruptive technology for novel sublingual delivery mechanisms for known drugs and supplements . The company expects to generate revenue through these efforts and may also pursue license or collaboration agreements . A key strategic priority is the advancement of its high-dose sublingual aspirin product, with a 505(b)(2) submission to the FDA planned for late 2026 , following positive clinical trial results demonstrating faster bioavailability and quicker anti-coagulant effects compared to conventional aspirin . Management also highlights the ongoing development of other products, including melatonin, vitamins D, E, and K, an ED medication, caffeine products under the "Buzz Bomb" trademark, and formulations for anti-nausea, alprazolam, clopidogrel, microdose nicotine, and semaglutide . The company acknowledges that its general and administrative, research and development, and sales and marketing expenses are expected to increase in future periods commensurate with business growth and its status as a public company . Management also notes the successful regaining of compliance with Nasdaq's Bid Price Rule on February 3, 2026, and the MVLS Rule on February 18, 2026 .

View Source Annual Report on SEC.gov ↗

References

  1. [1] Item 1, Business — Overview
  2. [2] Item 1, Business — Business Plan
  3. [3] Item 1, Business — Business Plan
  4. [4] Item 1, Business — Commercialization of Aspirin Products; Item 1, Business — Current Development Status of Other Products
  5. [5] Item 1, Business — Our Products
  6. [6] Item 1, Business — Our Products
  7. [7] Item 1, Business — Intellectual Property
  8. [8] Item 1, Business — Intellectual Property
  9. [9] Item 1, Business — Intellectual Property
  10. [10] Item 1, Business — Manufacturing
  11. [11] Item 1, Business — Manufacturing
  12. [12] Item 1, Business — Manufacturing
  13. [13] Item 1, Business — Our Products
  14. [14] Item 1, Business — Current Development Status of Other Products
  15. [15] Item 1, Business — Current Development Status of Other Products
  16. [16] Item 1, Business — Current Development Status of Other Products
  17. [17] Item 1, Business — Current Development Status of Other Products
  18. [18] Item 1, Business — Other Products
  19. [19] Item 7, MD&A — Results of Operations
  20. [20] Item 7, MD&A — Results of Operations
  21. [21] Item 7, MD&A — Results of Operations
  22. [22] Item 7, MD&A — Results of Operations
  23. [23] Item 7, MD&A — Results of Operations
  24. [24] Item 7, MD&A — Results of Operations
  25. [25] Item 7, MD&A — Results of Operations
  26. [26] Item 7, MD&A — Liquidity and Capital Resources
  27. [27] Item 7, MD&A — Liquidity and Capital Resources
  28. [28] Item 7, MD&A — Liquidity and Capital Resources
  29. [29] Item 7, MD&A — Results of Operations
  30. [30] Item 7, MD&A — Gross Profit
  31. [31] Item 7, MD&A — General and Administrative
  32. [32] Item 7, MD&A — General and Administrative
  33. [33] Item 7, MD&A — Research and Development
  34. [34] Item 7, MD&A — Research and Development
  35. [35] Item 7, MD&A — Sales and Marketing
  36. [36] Item 7, MD&A — Sales and Marketing
  37. [37] Item 7, MD&A — Results of Operations
  38. [38] Item 7, MD&A — Interest expense
  39. [39] Item 7, MD&A — Results of Operations
  40. [40] Item 7, MD&A — Results of Operations
  41. [41] Item 7, MD&A — Results of Operations
  42. [42] Item 1, Business — Recapitalization
  43. [43] Item 1, Business — Securities Purchase Agreement
  44. [44] Item 1, Business — Securities Purchase Agreement
  45. [45] Item 1, Business — Convertible Notes
  46. [46] Item 1, Business — Conversion of Notes
  47. [47] Item 1, Business — Second ELOC Agreement
  48. [48] Item 1, Business — Nasdaq Notices
  49. [49] Item 1, Business — Exchange Agreements
  50. [50] Item 1, Business — Exchange Agreements
  51. [51] Item 7, MD&A — Reverse Stock Split
  52. [52] Item 7, MD&A — Growth Strategy and Outlook
  53. [53] Item 7, MD&A — Growth Strategy and Outlook
  54. [54] Item 7, MD&A — Current Development Status of Aspire’s Aspirin Product
  55. [55] Item 7, MD&A — Commercialization of Aspirin Products
  56. [56] Item 7, MD&A — Current Development Status of Aspire’s Aspirin Product
  57. [57] Item 7, MD&A — Current Development Status of Aspire’s Aspirin Product
  58. [58] Item 7, MD&A — Current Development Status of Aspire’s Aspirin Product
  59. [59] Item 7, MD&A — Current Development Status of Other Products
  60. [60] Item 7, MD&A — Current Development Status of Other Products
  61. [61] Item 7, MD&A — Current Development Status of Other Products
  62. [62] Item 7, MD&A — Current Development Status of Other Products
  63. [63] Item 7, MD&A — Current Development Status of Other Products
  64. [64] Item 7, MD&A — Current Development Status of Other Products
  65. [65] Item 7, MD&A — General and Administrative
  66. [66] Item 7, MD&A — Research and Development
  67. [67] Item 7, MD&A — Sales and Marketing
  68. [68] Item 7, MD&A — Manufacturing
  69. [69] Item 7, MD&A — Manufacturing
  70. [70] Item 7, MD&A — Manufacturing
  71. [71] Item 7, MD&A — Liquidity and Capital Resources
  72. [72] Item 7, MD&A — Liquidity and Capital Resources
  73. [73] Item 7, MD&A — Liquidity and Capital Resources
  74. [74] Item 1A, Risk Factors — Risks related to our Business
  75. [75] Item 1A, Risk Factors — Risks related to our Business
  76. [76] Item 1A, Risk Factors — Aspire faces significant competition from other biotechnology and pharmaceutical companies, and its operating results will suffer if it fails to compete effectively.
  77. [77] Item 1A, Risk Factors — Aspire’s technology platforms and product candidates are based on novel technologies, and the development and regulatory approval pathway for such product candidates is unproven (in that all aspirin products previously approved by the FDA were administered orally rather than sublingually) and may never lead to marketable products.
  78. [78] Item 1A, Risk Factors — Clinical development involves a lengthy and expensive process with uncertain outcomes, and results of earlier studies and trials may not be predictive of future clinical trial results.
  79. [79] Item 1A, Risk Factors — Aspire’s product candidates may cause undesirable side effects or have other properties that could halt their clinical development, prevent their regulatory approval, limit their commercial potential, if approved, or result in significant negative consequences.
  80. [80] Item 1A, Risk Factors — Aspire relies and expects to continue to rely on third parties to manufacture its clinical product supplies, and Aspire intends to rely on third parties to produce and process its product candidates, if approved, and commercialization of any of Aspire’s product candidates could be stopped, delayed or made less profitable if those third parties fail to obtain approval of government regulators or fail to provide Aspire with sufficient quantities of drug product at acceptable quality levels or prices.
  81. [81] Item 1A, Risk Factors — International trade disputes, including U.S. trade tariffs and retaliatory tariffs, could adversely impact our business.
  82. [82] Item 1A, Risk Factors — Our business, operations, financial position and clinical development plans and timelines, could be materially adversely affected by the continuing military action in Ukraine and the war between Israel and Hamas.
  83. [83] Item 1A, Risk Factors — Instaprin Pharmaceuticals’ former Chief Executive officer, Donald A. Milne III, was convicted, on a conspiracy to commit securities fraud charge.
  84. [84] Item 1A, Risk Factors — Aspire’s business could be negatively impacted by cyber security threats, attacks and other disruptions.
  85. [85] Item 7, MD&A — Overview
  86. [86] Item 7, MD&A — Growth Strategy and Outlook
  87. [87] Item 7, MD&A — Current Development Status of Aspire’s Aspirin Product
  88. [88] Item 7, MD&A — Current Development Status of Aspire’s Aspirin Product
  89. [89] Item 7, MD&A — Current Development Status of Other Products
  90. [90] Item 7, MD&A — General and Administrative
  91. [91] Item 7, MD&A — Nasdaq Notices

Analysis on 5/22/2026